Skip to content

Prostate medication, metabolism and gut microbiota, PROMED.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-500618-24-00
Enrollment
100
Registered
2022-08-10
Start date
2022-12-01
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer, benign prostate hyperplasia

Brief summary

change of gut microbiota signature after two months of prostate medication (5-ARI, LhRH-analog/antagonist)

Detailed description

change of gut microbiota metabolism after two months of prostate medication (5-ARI, LhRH-analog/antagonist), PSA response to 5-ARI after 2 and 6 months of therapy, prostate volume change to 5-ARI treatment after 2 and 6 months of therapy, PSA response LhRH-analog/antagonist after 2 and 6 months of therapy

Interventions

DRUGDuodart 0
DRUG5 mg/0
DRUG4 mg hårda kapslar
DRUGFINASTERIDE
DRUGDUTASTERIDE

Sponsors

Turku University Central Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
change of gut microbiota signature after two months of prostate medication (5-ARI, LhRH-analog/antagonist)

Secondary

MeasureTime frame
change of gut microbiota metabolism after two months of prostate medication (5-ARI, LhRH-analog/antagonist), PSA response to 5-ARI after 2 and 6 months of therapy, prostate volume change to 5-ARI treatment after 2 and 6 months of therapy, PSA response LhRH-analog/antagonist after 2 and 6 months of therapy

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026